Snafi

Quick links to important sections

Snafi

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Snafi

What is Snafi? Defining the Therapeutic Entity and Class

The drug commercially known as Snafi is fundamentally defined by its active pharmaceutical ingredient, Tadalafil (INN). It is a prescription medication intended for use in adult men, manufactured for oral use, and classified based on its precise molecular action within the body.

Property Description
Active ingredient Tadalafil
Form Oral Tablets
Pharmacological class Phosphodiesterase type 5 (PDE5) Inhibitor
Common use Supporting improved erectile function
Origin Synthetic compound

Snafi: Defining the Tadalafil Entity and Pharmacological Class

Snafi is classified as a Phosphodiesterase type 5 (PDE5) Inhibitor, representing a distinct category of synthetic therapeutic compounds. Its core identity is the Tadalafil molecule, which is chemically a pyrazinopyridoindole derivative. This compound is clinically recognized for its selective and potent activity against the PDE5 enzyme.

Composition, Form, and Origin

Snafi is strictly a single-ingredient product, containing only the active compound Tadalafil alongside various solid pharmaceutical excipients necessary to form the tablet structure. Tadalafil is characterized as a purely synthetic substance, chemically manufactured rather than derived from natural sources. As a brand formulation of Tadalafil, Snafi presents the medication as oral tablets, which is the definitive dosage form and route of administration for this product.

General Purpose and Physiological Effect

The general purpose of Snafi is to enhance the body’s natural physiological response to sexual arousal by improving penile blood flow. Tadalafil achieves this by temporarily blocking the PDE5 enzyme, an action that sustains elevated levels of cGMP. This chemical preservation leads directly to the smooth muscle relaxation and resultant vasodilation (widening of blood vessels), providing the necessary vascular support. The long-lasting nature of Tadalafil allows for greater flexibility in managing typical use scenarios, facilitating stable erection only when the user is sexually stimulated.

Regulatory References

  1. National Institutes of Health (NIH)

What side effects are possible with Snafi?

The officially documented safety profile for Snafi (Tadalafil) is structured by regulatory bodies (such as the FDA and EMA) using established frequency categories to classify all reported adverse reactions. This classification maps the likelihood of an effect to the body system affected, ensuring clarity in the medicine’s risk profile.

Adverse Reaction Categories

Side effects are grouped by frequency and body system, aligning with the regulatory framework. Very Common (occurring in 1/10 or more patients) reactions include headache. Common reactions (occurring in 1/100 to 1/10 patients) involve the Musculoskeletal system (back pain, myalgia, pain in extremity), the Gastrointestinal system (dyspepsia, gastroesophageal reflux), and the Vascular system (flushing, nasal congestion).

Uncommon and Rare adverse reactions are also documented, including those related to Cardiac disorders (tachycardia, palpitations), Ear and Labyrinth disorders (tinnitus, sudden hearing loss), and Eye disorders (blurred vision).

Serious Adverse Reactions and Constraints

Regulatory documents highlight rare but clinically significant adverse reactions, including Priapism (a prolonged erection lasting over 4 hours), sudden decrease or loss of vision due to NAION (Non-arteritic anterior ischaemic optic neuropathy), and major cardiovascular events like stroke or myocardial infarction.

Use is contraindicated in patients simultaneously using any form of organic nitrate or guanylate cyclase stimulators. It is also not recommended for patients with severe hepatic or severe renal impairment due to limited data and increased drug exposure. Back pain and muscle aches are documented as being more common at higher doses and may exhibit a delayed onset of 12 to 24 hours after administration.

Overdose and Emergency Response

Overdose and when to seek help

In the event of an overdose, regulatory documents state that the primary manifestations are an increased incidence and severity of known adverse events, such as headache, flushing, dyspepsia, back pain, and myalgia. Single doses up to 500 mg have demonstrated this dose-dependent increase in symptoms. Immediate medical assistance must be sought if an overdose is suspected, as treatment is symptomatic and supportive due to the officially documented fact that no specific antidote is known.

Severe Outcomes Requiring Immediate Action

Specific outcomes require urgent attention as mandated by official labeling. Seek emergency medical assistance for Priapism, which is defined as a prolonged erection lasting 4 hours or more. This is a medical emergency that risks permanent tissue damage and potential loss of potency. Furthermore, immediate medical attention is required for any sudden decrease or loss of vision or sudden decrease or loss of hearing, as these events are explicitly documented as severe effects.

Management and Procedural Considerations

The regulatory profile confirms that treatment is limited to standard supportive measures adopted as required by the patient’s clinical state. A procedural limitation is also noted: Haemodialysis contributes negligibly to the elimination of Tadalafil from the body due to the drug’s high plasma protein binding.

Therapeutic Uses of Snafi

What Snafi Treats: Main Uses and Benefits

Snafi (Tadalafil) may be part of symptomatic management across several distinct therapeutic areas. The medication is commonly used to help with conditions that present with heightened symptoms and functional stress. This medication is applied in addressing three symptom-driven clinical presentations: Erectile Dysfunction (ED), troublesome Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH), and pulmonary issues related to Pulmonary Arterial Hypertension (PAH). The benefit contributes to easing the overall symptom load during these situations.

Supporting Vascular Function for Erectile Difficulties

Snafi is relevant for managing symptoms that interfere with daily comfort and may assist with maintaining functional stability upon sexual stimulation. This therapeutic application helps address symptoms related to organ-specific functional stress. “The medication may be applied across domains where additional symptomatic support is appropriate to maintain functional stability.”


Quick Fact: Relief for Urinary Symptoms

Snafi may be part of symptomatic management to address symptoms that become intense or disruptive, such as a weak urine stream, hesitancy, and the frequent or urgent need to urinate caused by BPH. This contributes to improved day-to-day comfort during symptomatic periods. The medication is relevant when supportive symptom management is appropriate.

Regulatory References

  1. NIH MedlinePlus Drug Information on Tadalafil

Eligibility and Restrictions for Use

Snafi (Tadalafil) is indicated for use in adult males for its primary uses; its eligibility is strictly defined by regulatory bodies based on a patient's concurrent medications and underlying health status.

Absolute Prohibitions (Contraindications)

Contraindicated Group Restriction Basis
Patients using organic nitrates (e.g., nitroglycerin) Risk of life-threatening hypotension
Patients using Guanylate Cyclase (GC) Stimulators Risk of dangerous drop in blood pressure
Patients with recent serious cardiovascular events Unstable cardiac status makes sexual activity inadvisable
Patients with history of NAION (sudden vision loss) Risk of recurrence

Eligibility Restrictions and Special Populations

Use is generally not recommended in several patient populations due to lack of safety data or altered drug clearance:

  • Severe Organ Impairment: Patients with severe hepatic impairment (Child-Pugh Class C) or severe renal impairment ( CrCl < 30 mL/min) are discouraged from using the medicine, particularly for once-daily dosing.
  • Age and Sex: The medicine is not indicated for the pediatric population, as safety and efficacy have not been established. It is also not indicated for use in women for the approved erectile dysfunction/BPH indications.

The regulatory profile strictly limits use to adults who do not possess these documented high-risk factors.

What should I know about interactions with other medicines?

The interaction profile of Snafi (Tadalafil) is defined by its effects on vascular tone and its primary metabolic pathway, as documented in regulatory prescribing information.

Formal Prohibitions and Restrictions

Co-administration with organic nitrates (any form) and Guanylate Cyclase (GC) stimulators, such as Riociguat, is formally contraindicated by regulatory bodies due to the documented potentiation of hypotensive effects. A mandatory separation time of at least 48 hours must elapse following the last Tadalafil dose before a nitrate can be administered. Concomitant use with other PDE5 inhibitors is not recommended.

Exposure and Clearance Alterations

Tadalafil is predominantly cleared via the CYP3A4 enzyme pathway. Co-administration with potent CYP3A4 inhibitors (e.g., Ritonavir, Ketoconazole) increases Tadalafil exposure (AUC). Conversely, CYP3A4 inducers (e.g., Rifampin) decrease Tadalafil exposure.

Pharmacodynamic Effects

Snafi may potentiate the hypotensive effects of certain agents. Concomitant use with alpha-blockers (e.g., Doxazosin) or other antihypertensives may result in symptomatic hypotension due to additive vasodilatory effects. Consumption of substantial amounts of alcohol (defined as 5 units) is associated with an increased potential for orthostatic hypotension.

Population-Specific Notes

Use is not recommended in patients with severe hepatic impairment due to the lack of sufficient regulatory data regarding Tadalafil exposure in this population.

Mechanism of Action

How Snafi Works: Pharmacodynamics

Snafi's mechanism of action is defined by the selective inhibition of the enzyme phosphodiesterase type 5 (PDE5). This inhibition occurs primarily in the vascular smooth muscle of specific circulatory beds. PDE5 is physiologically responsible for the hydrolysis (breakdown) of the intracellular signaling molecule cyclic Guanosine Monophosphate (cGMP). By blocking this enzymatic action, Snafi prevents cGMP degradation, leading to an elevated and sustained concentration of the molecule within the smooth muscle cells.

This elevated cGMP concentration then facilitates the relaxation of the surrounding smooth muscle tissue, a process termed myorelaxation. This muscular relaxation, acting via the nitric oxide (NO)-cGMP pathway, results in localized vasodilation (widening of the arteries). Vasodilation, in turn, increases blood flow within the affected tissues, which is the direct system-level physiological consequence of the drug's activity.

Dosage and Administration Information

How Snafi is used: Official Administration Guidelines

Snafi (Tadalafil) is strictly an oral medication available as film-coated tablets in four strengths: 2.5 mg, 5 mg, 10 mg, and 20 mg. Administration is consistent across all approved uses, and the dose may be taken with or without food. Tablets must be swallowed whole.


Standard Labeled Dosing Regimens

The maximum frequency for any regimen is once per day. Dosing is determined by the specific condition being managed.

Indication & Pattern Standard Starting Dose Maximum Dose (Once Daily) Timing Note
Erectile Difficulties (As-Needed) 10 mg 20 mg Take at least 30 minutes prior to sexual activity
Erectile Difficulties (Daily Use) 2.5 mg 5 mg Taken at approximately the same time each day
BPH/ED Daily Use 5 mg 5 mg Taken at approximately the same time each day
Pulmonary Arterial Hypertension (PAH) 40 mg (two 20 mg tablets) 40 mg Do not divide the dose over the day

Population-Based Administration Rules

Dosage adjustments are specified for specific patient groups:

  • Older Adults: No dose adjustment is required for geriatric patients based on age alone.
  • Severe Renal Impairment: Once-daily dosing is not recommended. The maximum recommended dose for as-needed use is significantly reduced (e.g., 5 mg every 72 hours, depending on regional label).
  • Severe Hepatic Impairment: Use is generally not recommended for any indication, as safety and efficacy have not been established in this group.

For continuous daily use regimens, such as those for BPH, the appropriateness of continued treatment should be reassessed periodically.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Snafi

This section provides an overview of the research that has studied the medicine Snafi (Tadalafil), focusing on the types of trials conducted and the patterns observed by official regulatory bodies. This summary is strictly for informational purposes and contains no clinical advice.


Research Evidence for Managing Erectile Dysfunction (ED)

Research in the research context of Erectile Dysfunction (ED) primarily relies on short-term randomized, controlled trials (RCTs). In these studies, adult men were evaluated in contexts involving fluctuating or unstable symptoms. The outcomes monitored in trials assessed patient-reported experiences, specifically using standardized tools like the International Index of Erectile Function (IIEF-EF) domain score to monitor functional changes.

Trials described patterns related to changes in the patient-reported IIEF-EF domain scores when comparing the study group to the placebo group. The evidence base includes longer-term open-label extensions, which observed the medication's use over periods of up to two years. However, high-quality, blinded, placebo-controlled trials designed to examine outcomes and potential changes over multiple years are still emerging, meaning long-term effects are not fully established.


Research Evidence for Lower Urinary Tract Symptoms (LUTS) in BPH

Snafi was studied for conditions associated with acute or disruptive episodes, specifically LUTS linked to Benign Prostatic Hyperplasia (BPH). The primary research involved randomized, double-blind, placebo-controlled trials typically lasting 12 to 26 weeks.

The trials were applied in studies examining patient-reported experiences, primarily measuring changes in the International Prostate Symptom Score (IPSS). Researchers examined objective measures such as urine flow rate in addition to the subjective symptom scores. In some studies, findings were mixed regarding changes in these objective measures, indicating that the reported symptom changes were associated with differences in the IPSS score, but not always a corresponding, consistent change in flow rate.


Key Uncertainties and Research Gaps

Comparative evidence is lacking for direct head-to-head trials against other similar medications in the regulatory evidence base. Results apply only to the populations studied, meaning findings may not directly translate to every individual. Furthermore, data for certain groups remain insufficient, such as for those with severe liver conditions, and sample sizes were modest in specific advanced age subsets.

Key Studies & References

  1. Tadalafil - StatPearls - NCBI Bookshelf (NIH)
  2. Role of application of tadalafil 5 mg once-daily (≥6 months) in men with erectile dysfunction from six randomized controlled trials

Frequently Asked Questions (FAQ)

Common questions about Snafi (FAQ)

Q: Does taking Snafi on an empty stomach make it work faster?

Official product information indicates that Snafi can be taken with or without food. Regulatory studies indicate that consuming the medication with food is not associated with a significant change in how quickly or to what extent the drug is absorbed into the body.


Q: Can Snafi affect my eyesight, like making colors look different or causing blurriness?

According to official sources, blurred vision is a documented adverse reaction. Furthermore, changes in color perception, such as seeing things with a blue-green tint, are noted as uncommon or rare adverse reactions with this class of medication.


Q: Is it true that Snafi can cause low blood pressure or dizziness?

Yes, regulatory documentation lists hypotension, or low blood pressure, as a potential adverse reaction. Related effects such as syncope (fainting) have also been documented. These effects are particularly noted when Snafi is used alongside other medications that also lower blood pressure.


Q: Does Snafi interact with grapefruit or grapefruit juice?

Official documents caution that Snafi's blood levels can be increased when taken with strong inhibitors of the CYP3A4 enzyme pathway. Substances like grapefruit or grapefruit juice are recognized as affecting the CYP3A4 pathway, and the official information notes the potential for increased drug levels when strong inhibitors are used.


Q: Does my age affect how well Snafi will work for me?

Clinical studies have examined the use of the drug in older adults, specifically those aged 65 and over. These studies examined the overall effectiveness and safety profiles, suggesting comparable outcomes to those seen in younger adults. Official product information notes that, based on age alone, no specific dose adjustment is typically needed.


Q: Why do some people experience headaches when taking Snafi?

Headaches are listed in official documents as a very common adverse reaction. This is related to the drug's primary physiological action, which involves vasodilation, or the widening of blood vessels throughout the body.


Q: Is the back pain from Snafi temporary, or does it continue the whole time?

Back pain and muscle aches are documented as common side effects. Regulatory documents indicate that these symptoms typically have a delayed onset, usually appearing 12 to 24 hours after administration. Official documentation indicates that these symptoms are typically transient and have been observed to resolve spontaneously within a few days of continued daily use or after the effect of an as-needed dose.


Q: Is Snafi a treatment for the underlying causes of a medical condition, or just the symptoms?

The official mechanism of action involves a temporary physiological effect: the widening of blood vessels. This effect helps relieve functional symptoms, such as those related to ED or BPH. The drug is not described in regulatory documents as a treatment that cures or eliminates the underlying causes of these medical conditions.


Q: Can Snafi be affected by a high-fat meal?

According to official product information, the drug can be taken with or without food. Regulatory studies indicate that consumption alongside a high-fat meal is not associated with a clinically significant change to the rate or extent of drug absorption.


Q: Why does Snafi sometimes cause flushing or redness in the face?

Flushing, often perceived as redness in the face, is listed as a common side effect. This is considered an expected outcome linked to the drug's primary mechanism of action: localized vasodilation, or the physical widening of blood vessels.


Q: How long does the effect of Snafi typically last?

Official documents note that the drug has a long duration of effect, which is primarily linked to its elimination rate from the body. The drug’s elimination rate from the body is characterized by a mean terminal half-life of approximately 17.5 hours in healthy individuals, which contributes to its long duration of effect.


Q: Can women use Snafi for sexual health issues?

The drug is approved for the treatment of erectile dysfunction and BPH in men. It is also approved for the treatment of Pulmonary Arterial Hypertension (PAH) in both men and women. The product is not officially indicated for female sexual health issues.


Q: Will Snafi increase my libido or sex drive?

The mechanism of action is based strictly on physiological changes related to blood flow. Official documents and clinical studies indicate that the drug's mechanism is not associated with an increase in a person’s sex drive or libido.


Q: Is it safe to use Snafi if I have a history of heart problems or a stroke?

Official documents place restrictions on who can use the drug based on their cardiovascular history. It is generally contraindicated for individuals with a recent history of heart attack, stroke, or conditions like unstable angina or uncontrolled blood pressure.


Q: Does the effectiveness of Snafi decrease over time?

Clinical data includes long-term open-label extension studies that tracked patients over extended periods. These studies reported observations suggesting that the drug's effectiveness was generally maintained over the observed period in the patient groups evaluated.


Q: Is it okay to use Snafi if I am taking other herbal supplements?

According to official information, caution is advised when using the drug alongside non-prescription or herbal supplements. This is because some supplements may interact with the drug's primary metabolic pathway, known as the CYP3A4 enzyme, potentially altering the drug's exposure.


Q: Will Snafi still work if I have high cholesterol or diabetes?

The patient populations in regulatory clinical trials included individuals with common co-morbidities. Studies examined the drug's use in groups that also had common co-morbidities such as high blood pressure, high cholesterol, and diabetes, reporting observed efficacy in these subpopulations.


Q: Can Snafi be used safely by younger men?

Regulatory documents specify that the drug is labeled for use in adult men. There is typically no specific dose adjustment or explicit prohibition mentioned for healthy younger adult men, as long as they meet the established criteria for use.


Q: Can Snafi affect my fertility or sperm count?

Clinical studies, including those lasting up to six months, have evaluated the drug's effect on sperm parameters. Official documents generally indicate that adverse effects on sperm count, mobility, or reproductive hormones were not observed in the men studied during clinical investigations.


Q: Does Snafi affect my testosterone levels?

The mechanism of the drug relates to local vasodilation and is not hormonal. Clinical studies have indicated that the drug is generally not associated with a significant effect on the circulating levels of testosterone or other key reproductive hormones.


Q: Can Snafi be used by individuals who have had prostate surgery?

Clinical data from regulatory studies include the evaluation of the drug in patients who have undergone specific surgical procedures, such as radical prostatectomy. The use in this population has been investigated in clinical trials.


Q: How often is Snafi reported to be effective in clinical studies?

Studies have provided specific efficacy results, such as the reported percentage of patients who experienced an improvement in functional scores (e.g., Sexual Encounter Profile Question 3 success rate). This rate is usually reported in comparison to the results seen in the placebo group across various doses.

How should Snafi be stored and disposed of?

Storage Requirements

Snafi (tadalafil) must be stored at Controlled Room Temperature, defined as 25 C (77 F), allowing for brief excursions between 15 C and 30 C (59 F and 86 F). The official label mandates storing the tablets in the original container to protect the product from moisture and direct light. It is a strict requirement that the medication be kept out of the sight and reach of children and must not be allowed to freeze.

Disposal Instructions

Disposal of unused or expired Snafi must comply with local regulations. Regulatory guidance recommends utilizing a drug take-back program when available. If a take-back program is not accessible, the tablets can be discarded in household trash after mixing them with an unappealing substance, such as coffee grounds or dirt. The medication must not be flushed down a toilet or drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Snafi found in:

A-Z Index: